Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system

A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079

The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214

Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients

(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941

A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure

Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108

The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

Pitt, B., Zannad, F. M., Remme, W. J., Cody, R. J., Castaigne, A., Pérez, A. J. P., Palensky, J., & Wittes, J. T. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604

New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval

Zannad, F. M., Rossignol, P., Stough, W. G., Epstein, M., García, M. D. L. A. A., Bakris, G. L., Butler, J., Kosiborod, M., Berman, L., Mebazaa, A., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.127 · Cited by 25

Clinical and Economic Burden of Hyperkalemia: A Nationwide Hospital-Based Cohort Study in Japan

Kanda, E., Kashihara, N., Kohsaka, S., Okami, S., & Yajima, T. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2020.09.003 · Cited by 25

Exposure of the elderly to potential nephrotoxic drug combinations in Belgium

Smets, H. L., Haes, J. F. D., Swaef, A. D., Jorens, P. G., & Verpooten, G. A. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1641 · Cited by 24

Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?

Majewski, C., & Bakris, G. L. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0713-y · Cited by 23

Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism

Poggio, R., Grancelli, H., & Miriuka, S. (2010) · Postgraduate Medical Journal · doi:10.1136/pgmj.2008.072058 · Cited by 23

Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease

Frimodt‐Møller, M., Nielsen, A. H., Strandgaard, S., & Kamper, A. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp547 · Cited by 23

Treatment of Hyperkalemia in Heart Failure

DeFilippis, E. M., & Desai, A. S. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0341-0 · Cited by 23

Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization

Desai, N. R., Rowan, C. G., Alvarez, P. J., Fogli, J., & Toto, R. D. (2020) · PLoS ONE · doi:10.1371/journal.pone.0226844 · Cited by 23

Cardiovascular and Renal Outcomes Associated With Hyperkalemia in Chronic Kidney Disease: A Hospital-Based Cohort Study

Kohsaka, S., Okami, S., Kanda, E., Kashihara, N., & Yajima, T. (2021) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2020.10.001 · Cited by 22

Optimizing Blood Pressure Control in Patients with Chronic Kidney Disease

Palmer, B. F., & Fenves, A. Z. (2010) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2010.11928626 · Cited by 24

Mineralocorticoid Receptor Antagonists and Cardiovascular Mortality in Patients With Atrial Fibrillation and Left Ventricular Dysfunction

O’Meara, E., Khairy, P., Chabot-Blanchet, M., de Denus, S., Pedersen, O. D., Lévesque, S., Talajic, M. R., Ducharme, A., White, M., Racine, N., et al. (2012) · Circulation Heart Failure · doi:10.1161/circheartfailure.111.965160 · Cited by 22

Efficacy and Safety of Patiromer in Hyperkalemia: A Systematic Review and Meta-Analysis

Das, S., Dey, J. K., Sen, S., & Mukherjee, R. (2017) · Journal of Pharmacy Practice · doi:10.1177/0897190017692921 · Cited by 22

Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments

Zannad, F. M., Ferreira, J. P., & Pitt, B. (2019) · European Heart Journal Supplements · doi:10.1093/eurheartj/suy034 · Cited by 22

Vascular Pharmacology

Harrison, D. G., & Luther, J. M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2930-6.00006-9 · Cited by 21

Angiotensin Receptor Blockers and the Risk of Cancer: Insights from Clinical Trials and Recent Drug Recalls

Berrido, A. M., & Byrd, J. B. (2020) · Current Hypertension Reports · doi:10.1007/s11906-020-1021-0 · Cited by 21

Clinical and electrocardiogram presentations of patients with high serum potassium concentrations within emergency settings: a prospective study

Raffee, L. A., Alawneh, K. Z., Ababneh, M. J., Hijazi, H. H. A., Abdi, R. M. A., Aboozour, M. M., Alghzawi, F., & Al-Mistarehi, A.-H. W. (2022) · International Journal of Emergency Medicine · doi:10.1186/s12245-022-00422-8 · Cited by 21

A randomized study to compare oral potassium binders in the treatment of acute hyperkalemia

Cañas, A. E., Troutt, H. R., Jiang, L., Tonthat, S., Darwish, O. S., Ferrey, A., Lotfipour, S., Kalantar‐Zadeh, K., Hanna, R. M., & Lau, W. L. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03145-x · Cited by 22

A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes

Fu, E. L., Mastrorilli, J. M., Bykov, K., Wexler, D. J., Cervone, A., Lin, K. J., Patorno, E., & Paik, J. M. (2023) · Kidney International · doi:10.1016/j.kint.2023.11.025 · Cited by 22

Overview of pyroptosis mechanism and in-depth analysis of cardiomyocyte pyroptosis mediated by NF-κB pathway in heart failure

Zhang, Z., Yang, Z., Wang, S., Wang, X., & Mao, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117367 · Cited by 22

Valoración de afección renal, disfunción renal aguda e hiperpotasemia por fármacos usados en cardiología y nefrotoxicidad por contrastes

Teruel, J. L., & Catalán, S. B. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.08.012 · Cited by 21

Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia

Kuijvenhoven, M. A., Haak, E. A. F., Handoko, K. B., & Crul, M. (2013) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-013-9830-8 · Cited by 21

Adverse safety events in patients with Chronic Kidney Disease (CKD)

Offurum, A. I., Wagner, L.-A., & Gooden, T. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1236909 · Cited by 21

Hyperkalaemia in people with diabetes: occurrence, risk factors and outcomes in a Danish population‐based cohort study

Thomsen, R. W., Nicolaisen, S. K., Adelborg, K., Svensson, E., Hasvold, P., Palaka, E., Pedersen, L. H., & Sørensen, H. T. (2018) · Diabetic Medicine · doi:10.1111/dme.13687 · Cited by 21

Cardio-renal insufficiency: the search for management strategies

Gil, P., Justo, S., Castilla, M. Á., Criado, C., & Caramelo, C. A. (2005) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000170753.41279.70 · Cited by 22

Potassium: A Frontier in Osteoporosis

Singh, W., & Kushwaha, P. (2024) · Hormone and Metabolic Research · doi:10.1055/a-2254-8533 · Cited by 20

Angiotensin II receptor blockade alleviates calcineurin inhibitor nephrotoxicity by restoring cyclooxygenase 2 expression in kidney cortex

Hu, J., Xu, Y., Bachmann, S., & Mutig, K. (2020) · Acta Physiologica · doi:10.1111/apha.13612 · Cited by 20

Association Between Dietary Potassium Intake Estimated From Multiple 24-Hour Urine Collections and Serum Potassium in Patients With CKD

Ogata, S., Akashi, Y., Kato, S., Oka, Y., Suda, A., Yoshizaki, S., Maeda, Y., Nishimura, K., Maeda, K., & Nakai, S. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.12.005 · Cited by 20

Supratherapeutic Doses of Angiotensin Receptor Blockers to Decrease Proteinuria in Patients with Chronic Kidney Disease

Palmer, B. F. (2007) · American Journal of Nephrology · doi:10.1159/000112270 · Cited by 20

The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation

Rangel, É. B. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.724058 · Cited by 20

Novel Agents for the Prevention and Management of Hyperkalemia

McCullough, P. A., Costanzo, M. R., Silver, M. T., Spinowitz, B., Zhang, J., & Lepor, N. E. (2015) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0782 · Cited by 20

Management of chronic kidney disease

Tomson, C., & Bailey, P. (2011) · Medicine · doi:10.1016/j.mpmed.2011.04.006 · Cited by 20

Advances in the management of hyperkalemia in chronic kidney disease

Cowan, A., Gharib, E. G., & Weir, M. A. (2017) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000320 · Cited by 20

Metabolic Acidosis

Palmer, B. F., & Alpern, R. J. (2010) · Elsevier eBooks · doi:10.1016/b978-0-323-05876-6.00012-5 · Cited by 20

Direct renin inhibition: an evaluation of the safety and tolerability of aliskiren

Rashid, H. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802336541 · Cited by 20

Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia

Rafique, Z., Peacock, W. F., LoVecchio, F., & Levy, P. D. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1066334 · Cited by 19

Adherence to Biochemical Monitoring Recommendations in Patients Starting with Renin Angiotensin System Inhibitors

Bootsma, J. E. M., Herwaarden, M. F. W.-V., Verbeek, A. L. M., Füssenich, P., Smet, P. A. G. M. D., Rikkert, M. G. M. O., & Kramers, C. (2011) · Drug Safety · doi:10.2165/11587250-000000000-00000 · Cited by 20

Onset time of hyperkalaemia after angiotensin receptor blocker initiation: when should we start serum potassium monitoring?

Park, I.-W., Sheen, S. S., Yoon, D., Lee, S., Shin, G., Kim, H., & Park, R. W. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12109 · Cited by 19

Complications métaboliques en insuffisance rénale chronique : hyperphosphatémie, hyperkaliémie et anémie

Hannedouche, T. P., Fouque, D. P., & Joly, D. (2018) · Néphrologie & Thérapeutique · doi:10.1016/s1769-7255(18)30647-3 · Cited by 19

Renal tubular acidosis type IV in hyperkalaemic patients – a fairy tale or reality?

Haas, C. S., Pohlenz, I., Lindner, U., Muck, P. M., Arand, J., Suefke, S., & Lehnert, H. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04446.x · Cited by 19

Managing hyperkalemia in high-risk patients in long-term care.

Kumar, R., Kanev, L., Woods, S. D., Brenner, M. S., & Smith, B. (2017) · PubMed · Cited by 19

Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care - The NephroTest study

for the NephroTest Study group, Wagner, S., Metzger, M., Flamant, M., Houillier, P., Haymann, J., Vrtovsnik, F., Thervet, É., Boffa, J., Massy, Z. A., et al. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0710-7 · Cited by 19

Improving BP Control with Combined Renin-Angiotensin System Blockade and Thiazide Diuretics in Hypertensive Patients with Diabetes Mellitus or Kidney Disease

Palmer, B. F. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200808010-00002 · Cited by 19

Mechanism of ferroptosis in heart failure: The role of the RAGE/TLR4-JNK1/2 pathway in cardiomyocyte ferroptosis and intervention strategies

Zhang, Z., Yang, Z., Wang, S., Wang, X., & Mao, J. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102770 · Cited by 18

A determination of the current causes of hyperkalaemia and whether they have changed over the past 25 years

Muschart, X., Boulouffe, C., Jamart, J., Nougon, G., Gérard, V., Cannière, L. D., & Vanpee, D. (2014) · Acta Clinica Belgica · doi:10.1179/0001551214z.00000000077 · Cited by 18

Renal dysfunction in acute congestive heart failure: a common problem for cardiologists and nephrologists

Graziani, G., Pini, D., Oldani, S., Cucchiari, D., Podestà, M. A., & Badalamenti, S. (2013) · Heart Failure Reviews · doi:10.1007/s10741-013-9416-5 · Cited by 18

Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes

Khan, M. S., & Lea, J. P. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03652-5 · Cited by 17

Management of hypertension in the transplant patient

Weir, M. R., & Salzberg, D. J. (2011) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2011.07.003 · Cited by 18

Hypertension Following Kidney Transplantation

Rubin, M. F. (2011) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2010.10.006 · Cited by 17

The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone

Bamberg, K., William‐Olsson, L., Johansson, U., Jansson‐Löfmark, R., & Hartleib‐Geschwindner, J. (2019) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320319827449 · Cited by 17

Hyperchloremic normal gap metabolic acidosis

Palmer, B. F., & Clegg, D. J. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.19.03059-1 · Cited by 17

The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury

Jaisser, F., Tan, X., Chi, S., Liu, J., Wang, P., Bush, M., Benn, V. J., Yang, Y. F., & Zhang, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.604928 · Cited by 17

Alteraciones electrolíticas y del equilibrio ácido-base en la enfermedad renal crónica avanzada

Arroyo, R. A. (2008) · Nefrología · Cited by 17

The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure

Pitt, B. (2011) · Heart Failure Reviews · doi:10.1007/s10741-011-9286-7 · Cited by 17

Treatment of Abnormalities of Potassium Homeostasis in CKD

Palmer, B. F., & Clegg, D. J. (2017) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.06.001 · Cited by 16

Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review

Fonseca, C., Brito, D. A., Branco, P. Q., Frazão, J. M., Silva‐Cardoso, J., & Bettencourt, P. (2020) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2020.03.015 · Cited by 16

Hypertension treatment update: Focus on direct renin inhibition

Fitzgerald, M. A. (2011) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2010.00589.x · Cited by 17

Hyperkalemia after the Publication of RALES

Cavallari, L. H., Vaitkus, P. T., & Groo, V. (2004) · New England Journal of Medicine · doi:10.1056/nejm200412023512320 · Cited by 16

Palatability and physical properties of potassium-binding resin RDX7675: comparison with sodium polystyrene sulfonate

Zann, V., McDermott, J., Jacobs, J. W., Davidson, J. P., Lin, F., Korner, P., Blanks, R. C., & Rosenbaum, D. P. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s143461 · Cited by 15

A practical guide to monitoring for adverse drug reactions during antihypertensive drug therapy

McDowell, S. E., Thomas, S. K., Coleman, J. J., Aronson, J. K., & Ferner, R. E. (2013) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2012.120137 · Cited by 15

Hyperkalemia as a Constraint to Therapy With Combination Renin‐Angiotensin System Blockade: The Elephant in the Room

Epstein, M. (2009) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2008.00071.x · Cited by 15

Renal Sodium Handling

Warnock, D. G., & Rossier, B. C. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005080886 · Cited by 15

Metabolic and toxicological considerations for diuretic therapy in patients with acute heart failure

Aspromonte, N., Cruz, D. N., Valle, R., Bonello, M., Marco Tubaro, U., Gambaro, G., Marchese, G., Santini, M., & Ronco, C. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.586629 · Cited by 15

Adaptation to Nephron Loss and Mechanisms of Progression in Chronic Kidney Disease

Taal, M. W., & Brenner, B. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10051-x · Cited by 15

Sodium Polystyrene Sulfonate and Cytomegalovirus-Associated Hemorrhagic Duodenitis: More than Meets the Eye

Gürtler, N., Hirt‐Minkowski, P., Brunner, S. S., König, K., Glatz, K., Reichenstein, D., Bassetti, S., & Osthoff, M. F. (2018) · American Journal of Case Reports · doi:10.12659/ajcr.910655 · Cited by 15

Use of Renin-Angiotensin System Blockers Increases Serum Potassium in Anuric Hemodialysis Patients

Movilli, E., Camerini, C., Gaggia, P., Zubani, R., & Cancarini, G. C. (2018) · American Journal of Nephrology · doi:10.1159/000491552 · Cited by 15

Renin-Angiotensin-Aldosterone System Blockade in Diabetes: Role of Direct Renin Inhibitors

Estacio, R. O. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.05.2000 · Cited by 15

Aldosterone antagonists: Silver bullet or just sodium excretion and potassium retention?

Wenzel, U. O. (2007) · Kidney International · doi:10.1038/sj.ki.5002141 · Cited by 15

Severe Hyperkalemic Type 4 Renal Tubular Acidosis After Kidney Transplantation: A Case Report

Rangel, É. B., Gomes, S. A., Machado, P. G. P., dos Santos, B. F. C., Pestana, J. O. M., Pacheco‐Silva, Á., & Heilberg, I. P. (2006) · Transplantation Proceedings · doi:10.1016/j.transproceed.2006.08.110 · Cited by 15

Fludrocortisone Therapy in Renal Transplant Recipients with Persistent Hyperkalemia

Marfo, K., & Glicklich, D. (2012) · Case Reports in Transplantation · doi:10.1155/2012/586859 · Cited by 15

The association between serum potassium and mortality in patients with hypertension: ‘a wake-up call’

Pitt, B., & Rossignol, P. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw209 · Cited by 15

Challenges of Glycemic Control in People With Diabetes and Advanced Kidney Disease and the Potential of Automated Insulin Delivery

Lu, J., Lee, P., Ierino, F. L., MacIsaac, R. J., Ekinci, E. I., & O'Neal, D. N. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231174040 · Cited by 15

Autonomic dysreflexia in urological practice: pathophysiology, prevention and treatment considerations

Calderón‐Juárez, M., Samejima, S., Rempel, L., Sachdeva, R., & Krassioukov, A. V. (2024) · World Journal of Urology · doi:10.1007/s00345-024-04781-0 · Cited by 14

Chronic Kidney Disease in Diabetes: A Clinical Practice Guideline

Tobe, S. W., BAJAJ, H. S., Tangri, N., Jain, R., Pham, T. T., Beaudin, V., & McFarlane, P. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.01.004 · Cited by 15

Methods for using clinical laboratory test results as baseline confounders in multi‐site observational database studies when missing data are expected

Raebel, M. A., Shetterly, S. M., Lu, C. Y., Flory, J., Gagne, J. J., Harrell, F. E., Haynes, K., Herrinton, L. J., Patorno, E., Popovic, J. R., et al. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4015 · Cited by 14

Machine Learning Models Predicting Cardiovascular and Renal Outcomes and Mortality in Patients with Hyperkalemia

Kanda, E., Okami, S., Kohsaka, S., Okada, M., Ma, X., Kimura, T., Shirakawa, K., & Yajima, T. (2022) · Nutrients · doi:10.3390/nu14214614 · Cited by 14

Malignancy diseases and kidneys: A nephrologist prospect and updated review

Habas, E. M., Akbar, R. A., Farfar, K., Arrayes, N., Habas, A., Rayani, A., Alfitori, G. B., Habas, E., Magassabi, Y., Ghazouani, H., et al. (2023) · Medicine · doi:10.1097/md.0000000000033505 · Cited by 14

The effect of renin–angiotensin system blockade on renal protection in chronic kidney disease patients with hyperkalemia

Lee, J.-H., Kwon, Y. E., Park, J. T., Lee, M. J., Oh, H. J., Han, S. H., Kang, S., Choi, K. H., & Yoo, T. (2014) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320313507122 · Cited by 14

Acid-Base, Electrolyte, and Metabolic Abnormalities

Faridi, A. B., & Weisberg, L. S. (2008) · Elsevier eBooks · doi:10.1016/b978-032304841-5.50060-1 · Cited by 14

Prevalence and correlates of hyperkalemia in a renal nutrition clinic

D’Alessandro, C., Cumetti, A., Pardini, E., Mannucci, C., Serio, P., Morganti, R., & Cupisti, A. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02353-9 · Cited by 14

Eplerenone

Keating, G. M., & Plosker, G. L. (2004) · Drugs · doi:10.2165/00003495-200464230-00005 · Cited by 14

Targeting ion homeostasis in metabolic diseases: Molecular mechanisms and targeted therapies

Zhang, Y., Ma, K., Fang, X., Zhang, Y., Miao, R., Guan, H., & Tian, J. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107579 · Cited by 13

Framework of Guidelines for Management of CKD in Asia

Pollock, C. A., Moon, J., Ha, L. P. N., Gojaseni, P., Ching, C. H., Gomez, L., Chan, T. M., Wu, M., Yeo, S. C., Nugroho, P., et al. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.12.010 · Cited by 12

Potassium and the Dyskalemias

Segal, A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3770-3_3 · Cited by 13

Équilibre potassique, hypokaliémie et hyperkaliémie

Dussol, B. (2010) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2010.03.004 · Cited by 13

Comparison of Hyperkalemic Risk in Hospitalized Patients Treated with Different Angiotensin Receptor Blockers

Park, I., Sheen, S. S., Lim, H., Yoon, D., Park, M. Y., Lee, S.-H., Shin, G., Kim, H., & Park, R. W. (2012) · American Journal of Cardiovascular Drugs · doi:10.1007/bf03261834 · Cited by 13

Hyperkalaemia in Heart Failure—Pathophysiology, Implications and Therapeutic Perspectives

Llubani, R., Vukadinović, D., Werner, C. M., Marx, N., Zewinger, S., & Böhm, M. (2018) · Current Heart Failure Reports · doi:10.1007/s11897-018-0413-9 · Cited by 13

Efficacy and safety of the pharmacotherapy used in the management of hyperkalemia: a systematic review

Varallo, F. R., Trombotto, V., Lucchetta, R. C., & Mastroianni, P. D. C. (2019) · Pharmacy Practice · doi:10.18549/pharmpract.2019.1.1361 · Cited by 13

Serum potassium abnormalities in chronic kidney disease: prevalence, patient characteristics and clinical outcomes

Brookes, E. M., Snider, J., Hart, G. K., Robbins, R., & Power, D. A. (2020) · Internal Medicine Journal · doi:10.1111/imj.14970 · Cited by 13

Biochemical Monitoring of Patients Treated with Antihypertensive Therapy for Adverse Drug Reactions

McDowell, S. E., & Ferner, R. E. (2011) · Drug Safety · doi:10.2165/11593980-000000000-00000 · Cited by 13

The Dark Side of Blocking RAS in Diabetic Patients with Incipient or Manifested Nephropathy

Bolignano, D., Pisano, A., & Coppolino, G. (2015) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0035-1550017 · Cited by 13

Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin‐Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction

Fang, G., Annis, I. E., Farley, J. F., Mahendraratnam, N., Hickson, R. P., Stürmer‎, T., & Robinson, J. G. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2051 · Cited by 13

Difficulties in maintaining potassium homeostasis in patients with heart failure

Dursun, İ., & Şahin, M. (2006) · Clinical Cardiology · doi:10.1002/clc.4960290904 · Cited by 13

Hypertension management in patients with chronic kidney disease

Palmer, B. F. (2008) · Current Hypertension Reports · doi:10.1007/s11906-008-0069-z · Cited by 13

EMCREG-International Multidisciplinary Consensus Panel on Management of Hyperkalemia in Chronic Kidney Disease and Heart Failure

Kreitzer, N. P., Albert, N. M., Amin, A., Beavers, C. J., Becker, R. C., Fonarow, G. C., Gibler, W. B., Kwon, K. W., Mentz, R. J., Palmer, B. F., et al. (2025) · Cardiorenal Medicine · doi:10.1159/000543385 · Cited by 14

Association of Potassium Level at Discharge with Long-Term Mortality in Hospitalized Patients with Heart Failure

Miura, Y., Higuchi, S., Kohno, T., Shiraishi, Y., Kitamura, M., Nagatomo, Y., Takei, M., Nakano, S., Goda, A., Soejima, K., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247358 · Cited by 13

A Data Mining Approach on Polypharmacy and Drug-drug Interactions of Common Diabetes Medications

Dwivedi, J., Kaushal, S., Wal, P., Chandrashekhar, D. J., Sharma, A., Nathiya, D., & Gasmi, A. (2025) · Current Drug Metabolism · doi:10.2174/0113892002358291250401190533 · Cited by 12

Renal Considerations in the Treatment of Hypertension

Palmer, B. F., & Clegg, D. J. (2018) · American Journal of Hypertension · doi:10.1093/ajh/hpy013 · Cited by 12

Increasingly restrictive definitions of hyperkalemia outcomes in a database study: effect on incidence estimates

Raebel, M. A., Ross, C. A., Cheetham, C., Petersen, H. V., Saylor, G., Smith, D. H., Wright, L., Roblin, D. W., & Xu, S. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1882 · Cited by 12

Pilot randomised double-blind controlled trial of high-dose spironolactone in critically ill patients receiving a frusemide infusion

Apte, Y., Bellomo, R., Warrillow, S. J., Goldsmith, D., Gillies, M., & McGain, F. (2008) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)01890-2 · Cited by 12

Current and future treatment options for managing hyperkalemia

Weir, M. R. (2016) · Kidney International Supplements · doi:10.1016/j.kisu.2016.01.005 · Cited by 12

Systematic Review Of Hyperkalemia Due To Angiotensin Enzyme Converting Inhibitors

Aggarwal, S., Topaloglu, H., & Kumar, S. (2015) · Value in Health · doi:10.1016/j.jval.2015.09.898

Systematic Review of Burden of Hyperkalemia due to Angiotensin Enzyme Converting Inhibitors

Aggarwal, S., Kumar, S., & Topaloglu, H. (2016) · Value in Health · doi:10.1016/j.jval.2016.03.082

Hyperkalemia and Inhibitors of the Renin–Angiotensin–Aldosterone System

Segal, A. Z. (2004) · New England Journal of Medicine · doi:10.1056/nejm200412023512321 · Cited by 2

Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Closer Look at Hyperkalemia

Chung, S., & Park, C. W. (2011) · The Korean Journal of Internal Medicine

Hyperkalemia Associated with Use of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

Raebel, M. A. (2011) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00258.x · Cited by 190